| Basics |
Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system, or ProCellEx.
|
| IPO Date: |
June 1, 1998 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$139.13M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.16 | 2.84%
|
| Avg Daily Range (30 D): |
$0.05 | 2.55%
|
| Avg Daily Range (90 D): |
$0.06 | 2.94%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.45M |
| Avg Daily Volume (30 D): |
.54M |
| Avg Daily Volume (90 D): |
.67M |
| Trade Size |
| Avg Trade Size (Sh.): |
332 |
| Avg Trade Size (Sh.) (30 D): |
159 |
| Avg Trade Size (Sh.) (90 D): |
211 |
| Institutional Trades |
| Total Inst.Trades: |
279 |
| Avg Inst. Trade: |
$1.62M |
| Avg Inst. Trade (30 D): |
$.58M |
| Avg Inst. Trade (90 D): |
$.58M |
| Avg Inst. Trade Volume: |
.11M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$5M |
| Avg Closing Trade (30 D): |
$.58M |
| Avg Closing Trade (90 D): |
$.58M |
| Avg Closing Volume: |
628.06K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$.08
|
$.03
|
|
|
Diluted EPS
|
$.08
|
$.03
|
|
|
Revenue
|
$ 61.84M
|
$ 17.85M
|
$
|
|
Gross Profit
|
$ 35.58M
|
$ 9.53M
|
$
|
|
Net Income / Loss
|
$ 5.39M
|
$ 2.36M
|
$
|
|
Operating Income / Loss
|
$ 6.37M
|
$ 2.13M
|
$
|
|
Cost of Revenue
|
$ 26.26M
|
$ 8.32M
|
$
|
|
Net Cash Flow
|
$ -13.8M
|
$
|
$
|
|
PE Ratio
|
21.63
|
|
|
| Splits |
|
Dec 20, 2019:
1:10
|
|
Jan 03, 2007:
1:10
|
|
|
|
